Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses

Hims & Hers Health announced its entry into the Canadian market to offer generic semaglutide, capitalizing on Novo Nordisk's patent lapse in Canada due to unpaid maintenance fees. This strategic move positions Hims & Hers to tap into Canada's rapidly growing semaglutide market, projected to reach $4.03 billion by 2035, and marks a significant international expansion for the telehealth platform. While regulatory approval for generic semaglutide is still pending in Canada, this development intensifies competition in the lucrative GLP-1 weight loss drug sector, potentially increasing accessibility and affordability for consumers.

Analysis

Hims & Hers Health (HIMS) is strategically entering the Canadian market to offer generic semaglutide, capitalizing on a significant misstep by Novo Nordisk (NVO), whose patent for Ozempic and Wegovy is lapsing in January due to unpaid maintenance fees dating back to 2018. This move positions HIMS to capture a share of the Canadian semaglutide market, which is projected to grow from $1.18 billion in 2024 to $4.03 billion by 2035. The entry represents HIMS's first operation in Canada and is part of a broader international expansion, evidenced by its recent acquisition of European telehealth platform Zava. While HIMS joins other generic players like Sandoz in seeking approval from Health Canada, the company has not confirmed if it has filed its own application, stating only that it is working with an "approved partner." The development is a material negative for Novo Nordisk, which not only loses patent protection through an avoidable administrative error but also faces intensified competition as its drug Wegovy already contends with Eli Lilly's Zepbound in the U.S. market. The prior termination of the collaboration between NVO and HIMS over promotional practices adds another layer of competitive tension to this market entry.

Key Decisions for Investors

• For Hims & Hers Health (HIMS), this entry into the Canadian market represents a significant, high-growth revenue catalyst, but investors should closely monitor for confirmation of regulatory approval from Health Canada, which is the key remaining hurdle.
• For Novo Nordisk (NVO), the premature loss of its Canadian patent due to an administrative oversight introduces immediate generic competition and signals a potential weakness in its intellectual property management, warranting closer scrutiny of its global patent portfolio.
• The move by a telehealth platform to distribute generic GLP-1s could signal a disruptive trend in pharmaceutical distribution, potentially benefiting consumers with lower prices but increasing margin pressure on branded drug manufacturers like Novo Nordisk and Eli Lilly.